Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2015 1
2016 2
2017 1
2020 3
2021 1
2022 1
2024 4
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean roberto vector (178 results)?
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). European Association for the Study of the Liver (EASL), et al. J Hepatol. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031. Epub 2024 Jun 7. J Hepatol. 2024. PMID: 38851997 Free article.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Marso SP, et al. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15. N Engl J Med. 2016. PMID: 27633186 Free article. Clinical Trial.
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
European Association for the Study of the Liver; European Association for the Study of Diabetes; European Association for the Study of Obesity. European Association for the Study of the Liver, et al. Diabetologia. 2024 Nov;67(11):2375-2392. doi: 10.1007/s00125-024-06196-3. Diabetologia. 2024. PMID: 38869512 Free PMC article.
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. Pi-Sunyer X, et al. N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892. N Engl J Med. 2015. PMID: 26132939 Free article. Clinical Trial.
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, Lingvay I, Colhoun HM, Plutzky J, Kosiborod MN, Hovingh GK, Hardt-Lindberg S, Frenkel O, Weeke PE, Rasmussen S, Goudev A, Lang CC, Urina-Triana M, Pietilä M, Lincoff AM; SELECT Trial Investigators. Deanfield J, et al. Lancet. 2024 Aug 24;404(10454):773-786. doi: 10.1016/S0140-6736(24)01498-3. Lancet. 2024. PMID: 39181597 Free article. Clinical Trial.
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). European Association for the Study of the Liver (EASL), et al. J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004. Epub 2016 Apr 7. J Hepatol. 2016. PMID: 27062661 No abstract available.
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group. le Roux CW, et al. Lancet. 2017 Apr 8;389(10077):1399-1409. doi: 10.1016/S0140-6736(17)30069-7. Epub 2017 Feb 23. Lancet. 2017. PMID: 28237263 Free article. Clinical Trial.
Spot-light on microbiota in obesity and cancer.
Marzullo P, Bettini S, Menafra D, Aprano S, Muscogiuri G, Barrea L, Savastano S, Colao A; Obesity Programs of nutrition, Education, Research and Assessment (OPERA) group. Marzullo P, et al. Int J Obes (Lond). 2021 Nov;45(11):2291-2299. doi: 10.1038/s41366-021-00866-7. Epub 2021 Aug 6. Int J Obes (Lond). 2021. PMID: 34363002 Free article. Review.
Publisher Correction: EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
European Association for the Study of the Liver; European Association for the Study of Diabetes; European Association for the Study of Obesity. European Association for the Study of the Liver, et al. Diabetologia. 2024 Nov;67(11):2608. doi: 10.1007/s00125-024-06258-6. Diabetologia. 2024. PMID: 39352523 Free PMC article. No abstract available.
Assessing Europe's policy readiness to confront the MASLD/MASH public health threat.
Lazarus JV, White TM, Agirre-Garrido L, Abeysekera KWM, Brennan PN, Brůha R, Buttigieg S, Carrieri P, Cortez-Pinto H, Flisiak R, Francque SMA, Frühbeck G, Gheorghe LS, Hagström H, Holleboom AG, Ivanov K, Jensterle M, Jepsen P, Kupčinskas J, Mark HE, Mauricio D, Bibi SM, Moreno C, Mrzljak A, Papanicolaou E, Papp M, Papatheodoridis G, Peck-Radosavljevic M, Pugliese N, Ryan JD, Ribeiro RT, Salupere R, Skladany L, Tolmane I, Yki-Järvinen H, Schattenberg JM, Pericàs JM; European MASLD collaborator group. Lazarus JV, et al. Lancet Reg Health Eur. 2026 May 25;65:101713. doi: 10.1016/j.lanepe.2026.101713. eCollection 2026 Jun. Lancet Reg Health Eur. 2026. PMID: 42266904 Free PMC article. Review.
16 results